Satralizumab, previously known as the SA-237 molecule, represents a promising therapy for a form of multiple sclerosis and other autoimmune ailments. Emerging clinical trials have shown encouraging https://dirstop.com/story28352521/satralizumab-a-deep-dive-into-sa-237-s-research-progress